How much is a tumor like a wound?  Will tumor cells interact with the body’s normal muscle stem cells, co-opting them for advantage to the tumor?  Can IL-4 Receptor antibodies block this process? These are the questions in our NIH R01 grant application that was scored this week in the top 4% of grants for that review cycle (usually, the top 9% of grants are funded).  We’re very excited about this grant, and the probable 5 years of funding to pursue these question that we think will benefit patients with rhabdomyosarcoma in a tangible way.  Kudos to Megan, who took strong work by Imran, Tohru and GH to the next level and made this project possible. 

Share this post
Share on facebook
Facebook
Share on google
Google+
Share on twitter
Twitter
Share on linkedin
LinkedIn
Close Menu